Advanced search
Start date
Betweenand

Effect of pharmacological and non-pharmacological treatment on the expression of the protein tyrosine phosphatase, receptor type D(PTPRD) and its relation with the Restless Legs Syndrome in SHR rats

Grant number: 18/05245-5
Support type:Regular Research Grants
Duration: August 01, 2018 - July 31, 2020
Field of knowledge:Health Sciences - Physical Education
Principal Investigator:Andrea Maculano Esteves
Grantee:Andrea Maculano Esteves
Home Institution: Faculdade de Ciências Aplicadas (FCA). Universidade Estadual de Campinas (UNICAMP). Limeira , SP, Brazil
Assoc. researchers:Adriana Souza Torsoni

Abstract

The Restless Leg Syndrome (RLS) is a common neurological sensorimotor disorder, manifested as an uncontrollable desire to move the body (legs) to relieve uncomfortable sensations. Recent studies show that variations in the PTPRD gene (Protein Tyrosine Phosphatase Receptor Type Delta) may increase the chance of developing this syndrome. The treatment for RLS may be pharmacological - medicines, or non-pharmacological - physical exercise (PE). This study aims to characterize the expression of PTPRD in SHR (Spontaneously Hypertensive Rats) animals and to verify the influence of pharmacological treatment (pramipexole - PPX), as well as non - pharmacological (physical exercise - PE) on the symptoms of RLS, sleep pattern and PTPRD expression. For this, SHR animals will be distributed in 5 groups: 1) Standard control (Wistar); 2) Control (SHR) 3) PE; 4) PPX; 5) PPX + PE; 6)A11 lesion. The intervention period will be 4 weeks. Treatment of the control and PE groups will consist of a saline vehicle. For the PPX and PPX + PE groups, the treatment will be performed at a dose of 0.1 mg / kg. All groups will receive saline / PPX daily. The PE will be performed on a treadmill, with 5 sessions per week lasting 1 hour each (moderate intensity). Electrocorticographic and electromyographic analyzes will be performed as well as the assessment of blood pressure. After the interventions, animals will be euthanized, followed by tissue extraction for the analysis of PTPRD, dopamine transporter, tyrosine hydroxylase, dopamine D2 receptor, iron, transferrin and ferritin by qPCR (Quantitative Polymerase Chain Reaction and Quantitative Polymerase Chain Reaction), Western Blotting and Elisa. The software that will be used for data analysis will be Statistica. (AU)